Overview


According to FutureWise analysis the market for antiviral therapeutics is expected to register a CAGR of 4.8% from 2023-2031.

These minute pathogens, only visible under a microscope, carry genetic information encapsulated within a protective layer. In contrast to human cells that house intricate machinery, viruses lack such systems, requiring them to infiltrate host cells to reproduce. Consequently, their replication process leads to the manifestation of viral illnesses. Viral infections can affect various bodily systems, causing flu-like representations, respiratory issues, digestive disturbances, skin conditions, and neurological complications. They have the potential to be contracted via exposure to infected individuals, surfaces carrying contaminants, engaging in sexual activities, experiencing animal bites, and consuming food or water that is tainted. Common viral infections include influenza, common cold, and hepatitis. 

Viruses can be diagnosed through swabs, blood tests, imaging, and body fluid analyses. Management often relies on antiviral medications, convalescent plasma, or post-exposure prophylaxis, with antibiotics ineffective against viral infections. Antiviral medications constitute a category of drugs employed in managing viral infections. While many antivirals are designed to target specific viruses, some encompass a broader spectrum of efficacy, spanning multiple viral strains. Antiviral drugs are prominent in antimicrobials, including antibiotics, antifungals, antiparasitic medicines, and monoclonal antibody-based antivirals. Notably, these medications are generally considered safe for the host and can be used to address infections. It is crucial to differentiate antiviral drugs from virucides, which are substances that deactivate or eliminate virus particles within or outside the body. Some natural virucides, like those derived from plants such as eucalyptus and Australian tea trees, possess this ability.

FutureWise Market Research has published a report that provides an insightful analysis of Antiviral Therapeutics Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts’ projects that Antiviral Therapeutics Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Gilead Sciences
  • F. Hoffmann-La Roche Ltd
  • Bristol Myers Squibb
  • GlaxoSmithKline plc.
  • Aurobindo Pharma
  • Merck & Co.
  • Johnson & Johnson Services
  • AbbVie
  • Cipla
  • Schering-Plough Corporation

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Class

  • Neuraminidase inhibitors
  • DNA polymerase inhibitors
    • Purine Nucleoside Analogues
    • Pyrimidine Nucleoside Analogues
    • Non-nucleosides
  • Reverse transcriptase inhibitors
    • Nucleoside RTIs
    • Nonnucleoside RTIs
    • Nucleotide RTIs
  • Protease inhibitors

By Application

  • Influenza
  • Hepatitis
    • Hepatitis B
    • Hepatitis C
  • Sexually Transmitted Diseases (STDs)
    • Herpes
    • HIV
    • Others
  • Respiratory tract infection
  • Others

By Distribution Channel

  • Brick and mortar
  • Hospital pharmacy
  • E-pharmacy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Antiviral Therapeutics Market By Drug Class, By Application, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Antiviral Therapeutics Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antiviral Therapeutics Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Antiviral Therapeutics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Antiviral Therapeutics Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Neuraminidase inhibitors
        2. DNA polymerase inhibitors
         2.1. Purine Nucleoside Analogues
         2.2. Pyrimidine Nucleoside Analogues
         2.3. Non-nucleosides
        3. Reverse transcriptase inhibitors
         3.1. Nucleoside RTIs
         3.2. Nonnucleoside RTIs
         3.3. Nucleotide RTIs
        4. Protease inhibitors

  • 8.   Antiviral Therapeutics Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Influenza
        2. Hepatitis
         2.1. Hepatitis B
         2.2. Hepatitis C
        3. Sexually Transmitted Diseases (STDs)
         3.1. Herpes
         3.2. HIV
         3.3. Others
        4. Respiratory tract infection
        5. Others

  • 9.   Antiviral Therapeutics Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Brick and mortar
        2. Hospital pharmacy
        3. E-pharmacy

  • 10.   North America Antiviral Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Antiviral Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Antiviral Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Antiviral Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Gilead Sciences
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. F. Hoffmann-La Roche Ltd
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Bristol Myers Squibb
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. GlaxoSmithKline plc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Aurobindo Pharma
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Merck & Co.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Johnson & Johnson Services
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. AbbVie
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Cipla
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Schering-Plough Corporation
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client

Related Market

Antiviral Drugs Market

Read More

Antiviral and Antimicrobial Coatings Market

Read More

Influenza Antiviral Market

Read More
Partner

Our Clients